The cut down in the lab in lab program now, towards the tail end of the pandemic, tells us that the lab in lab program is a failure, imo.
If it was viable the board would be moving towards getting more funding from by approaching investors with evidence that the funding will not be wasted.
Instead we are getting restructuring costs for yet another shift in the business model, this time into online sales.
The failure of the lab in lab model now suggests that the product itself is not marketable. Clearly very few centres have managed to sell more than a couple of units each month.
- Forums
- ASX - By Stock
- OVN
- Ann: Quarterly Business Review & Appendix 4C
Ann: Quarterly Business Review & Appendix 4C, page-9
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OVN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online